Factors that include sex, geographical area, work status and choice of accompanying drugs play a role in determining the use of a drug in a narcolepsy patient. This corresponds to a summary published in the newspaper Sleep and presented at the SLEEP 2017 conference.
The researchers studied 970 evaluations involving 849 patients with narcolepsy. Prior to this publication, researchers noted that there were no studies indicating people with narcolepsy to use, combine, or stop different drugs.
This study revealed specific demographic characteristics common to the participants for certain drugs against narcolepsy. For example, participants who reported using sodium oxybate (also known as Xyrem brand) lived mainly in the United States, mostly men, generally had a four-year university diploma and sodium oxybate to relieve symptoms within 1 to 5 years after diagnosis of narcolepsy to treat.
At the heart of the study was the information they trusted. The Nexus Narcolepsy Registry, an online database that follows a large number of people with narcolepsy, was launched in June 2015 and allowed patients to quantify the impact of the disease on their lives from a point of view multidimensional approach that included treatment methods. For this study, participants in Registry 2 examined bi-monthly reviews that asked questions about their current drug use and demographic information.
The study found that 92% of participants took 1 or more drugs to manage their symptoms. According to the survey, about 58% of participants in stimulants, 45% on antidepressants, 41% were on modafinil (also known as the Provigil brand) and armaphine (also known as Nuvigil) and 29 , 9% sodium oxybate. Among the participants in the study, modafinil and armodafinil had the highest death (23.9%) and sodium oxybate had the lowest stop (8.9%).
"We believe these data will help characterize the influence of narcolepsy on a patient's quality of life. We hope that this data can help improve disease control and patient outcomes," said David Pasta , co-founder. - author of the study and vice president of statistical analysis of medical affairs at ICON Biostatistics & Programming, by e-mail.
As our understanding of the drug against narcolepsy continues to grow, Kristin Rogers, head of Global Business Communication for Jazz Pharmaceuticals, noted in an email to Sleep Review that there are new drugs underway that are also suitable for being an option viable.
One of the early stages of development is a version of sodium oxybate to be taken only once a night as opposed to the current diet of a second dose taken in the middle of the night. In addition, Jazz Pharmaceuticals (the manufacturer of Xyrem) announced that JZP-110 has shown positive efficacy results for patients with narcolepsy who suffer from obstructive sleep apnea in comorbidity.
No comments:
Post a Comment